Kura Oncology's Q3 KOMZIFTI revenue rises 53% sequentially

Overview

• US biopharma firm's Q3 KOMZIFTI revenue rose 53% sequentially to $13.9 mln

• Collaboration revenue fell year-over-year, while net loss narrowed from Q3 2025

• Company ended Q3 with $492.1 mln in cash and short-term investments

Outlook

• Kura Oncology updates 2026 collaboration revenue guidance to $40 mln-$45 mln

• Company maintains collaboration revenue guidance of $90 mln-$110 mln for 2027 and 2028

• Company expects financial resources to support operations beyond initial topline results from KOMET-017 in 2028

Result Drivers

• KOMZIFTI GROWTH - KOMZIFTI net product revenue rose 53% sequentially to $13.9 mln, driven by a 30% increase in new patient starts and a 65% rise in total prescriptions; company maintained majority share of new patient starts in its class

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Kura Oncology, Inc. is $28.00, about 269.9% above its November 9 closing price of $7.57

Reuters Recommended Reads

• Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%

• Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook

• Nov 10 - Scholar Rock posts first product revenue after ISEMBYLD launch

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)